Pharmaceutical

Daiichi Sankyo and MSD withdraw US application for lung cancer BLA

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung cancer (NSCLC).

May 30, 2025 - 06:00
Daiichi Sankyo and MSD withdraw US application for lung cancer BLA
Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung cancer (NSCLC).
Read the original article

Tags:

Previous Article

New Study Reveals Depression Raises Dementia Risk in Midlife and Beyond

Next Article

HHS cancels $766m bird flu vaccine contract with Moderna

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Viz.ai, Sanofi and Regeneron to link for COPD management

Viz.ai, Sanofi and Regeneron to link for COPD management

May 22, 2025

STAT+: Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs

STAT+: Key senators blast Medicare Advantage insurers f...

Mar 24, 2023

Momentum Biotechnologies and Cube Biotech link for therapeutic solutions

Momentum Biotechnologies and Cube Biotech link for ther...

Aug 11, 2024